文献速递妇科

改善吲哚菁绿在子宫内膜癌前哨淋巴结定位中的技巧与策略

Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2018-06-15

本研究回顾了2014年2月至2015年12月接受初次手术的119例子宫内膜癌患者,术中使用吲哚菁绿(ICG)行前哨淋巴结(SLN)定位并随后行盆腔淋巴结清扫。总体检测率为93%,双侧检测率为74%;双侧检测患者中灵敏度和阴性预测值均为100%,至少单侧检测患者中分别为95%和99%。晚期FIGO分期(III或IV期)是唯一与双侧检测失败相关的因素(p=0.01)。

要点

  • ICG是子宫内膜癌SLN定位的优秀示踪剂,总体检测率93%,双侧检测率74%。
  • 双侧检测患者中灵敏度和阴性预测值均为100%;至少单侧检测患者中分别为95%和99%。
  • 晚期FIGO分期(III或IV期)是双侧检测失败的独立相关因素(p=0.01)。

核心结论

  • ICG是子宫内膜癌前哨淋巴结定位的优秀示踪剂。
  • 晚期FIGO分期与双侧检测失败相关(p=0.01)。
  • 无论定位结果如何,临床可疑淋巴结均应切除。
  • 应注意确保SLN标本实际包含淋巴结组织而非仅肿胀的淋巴管,这是SLN定位失败的重要原因。

研究设计与样本

  • 回顾性分析2014年2月至2015年12月接受初次手术的子宫内膜癌患者,术中使用ICG行SLN定位并随后行盆腔淋巴结清扫,共纳入119例。
  • SLN最终病理行超分期,前瞻性收集患者人口学、手术方式和组织病理学因素。
  • 计算检测率、灵敏度和阴性预测值,并行单因素分析评估与双侧SLN检测失败相关的因素。

主要发现

  • 总体检测率为93%,双侧检测率为74%。
  • 双侧检测患者中灵敏度和阴性预测值均为100%;至少单侧检测患者中灵敏度为95%、阴性预测值为99%。
  • 晚期FIGO分期(III或IV期)是唯一与双侧检测失败相关的因素(p=0.01)。
  • 14个半骨盆中标记为SLN的标本最终病理未含淋巴结组织(仅淋巴管),占「检测失败」病例的37%。
  • 1例假阴性发生于同侧临床可疑肿大淋巴结的患者。

临床怎么用

  • 作者认为ICG是子宫内膜癌SLN定位的优秀示踪剂。
  • 作者建议无论定位结果如何,临床可疑淋巴结均应切除。
  • 作者建议应注意确保SLN标本实际包含淋巴结组织而非仅肿胀的淋巴管。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the validity of sentinel lymph node (SLN) biopsy with ICG in endometrial cancer and to evaluate the factors associated with poor mapping or false negative. METHODS: We reviewed all patients who underwent primary surgery for endometrial carcinoma with SLN mapping using ICG followed by pelvic lymphadenectomy from February 2014 to December 2015. SLNs were ultrastaged on final pathology. Patients' demographics, surgical approach and histopathological factors were prospectively collected. Detection rate, sensitivity and negative predictive value (NPV) were calculated and univariate analysis was performed to evaluate factors associated with failed bilateral detection of SLNs. RESULTS: A total of 119 patients were included. The overall and bilateral detection rates were 93% and 74%. Sensitivity and NPV were 100% in patients with bilateral detection; 95% and 99% respectively in cases with at least unilateral detection. Advanced FIGO stage (III or IV) was the only factor related to failed bilateral detection (p = 0.01). In 14 hemi-pelvis, the specimen labelled as SLN did not contain nodal tissue on final pathology (only lymphatic channels), which represented 37% of the "failed detection" cases. One false negative occurred in a patient with an ipsilateral clinically suspicious enlarged lymph node. CONCLUSION: ICG is an excellent tracer for SLN mapping in endometrial cancer. Advanced FIGO stage correlated with failed bilateral detection (p = 0.01). Suspicious lymph nodes should be removed regardless of the mapping. Care should be taken to ensure that SLN specimen actually contains nodal tissue and not only swollen lymphatic channels, as this represents a significant cause of failed SLN mapping.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Body N, Grégoire J, Renaud MC, et al. Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer. Gynecol Oncol. 2018. PMID: 29909967. doi:10.1016/j.ygyno.2018.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。